| Literature DB >> 30636518 |
Peter Se Davies1, Simon M Graham2,3, Sithombo Maqungo4, William J Harrison5.
Abstract
Outcomes of arthroplasty in sub-Saharan Africa are not widely reported. To our knowledge, this systematic review is the first to explore this topic. Scopus, EMBASE, Medline and PubMed databases were searched, utilising MeSH headings and Boolean search strategies. All papers from South Africa were excluded. Twelve papers reporting 606 total hip replacements (THRs) and 763 total knee replacements (TKRs) were included. Avascular necrosis was the most common indication for THR, whereas osteoarthritis was the main indication for TKR. HIV prevalence of up to 33% was seen. Improvements were seen in patient-reported outcome measures in both THR and TKR. The dislocation rate in THR was 1.6%. The deep infection rate was 1.6% for TKRs and 0.5% for THRs. Positive results were reported, with comparable complications to high-income countries. However, there is likely to be significant reporting bias and the introduction of mandatory registries would enable more accurate monitoring across the region.Entities:
Keywords: Africa; THR; TKR; registry; sub-Saharan; total hip replacement; total knee replacement
Mesh:
Year: 2019 PMID: 30636518 PMCID: PMC6535807 DOI: 10.1177/0049475518822239
Source DB: PubMed Journal: Trop Doct ISSN: 0049-4755 Impact factor: 0.731
Inclusion and exclusion criteria.
| Type of criteria | Description | Rationale |
|---|---|---|
| Inclusion | Short- or long-term outcomes of total knee or hip TJR | As per research question |
| Performed in SSA | As per research question | |
| Studies produced in last 20 years | To maximise inclusion | |
| Exclusion | Studies performed in South Africa | Outlier in terms of development |
| Study not available in English | To minimise error |
MeSH headings.
| Group 1 (OR) | AND | Group 2 (OR) |
|---|---|---|
| Total knee | Africa | |
| TKR | Sub-Saharan | |
| TJR | Poor country | |
| Knee replacement | Developing country | |
| Hip replacement | ||
| THR | ||
| Total hip |
Figure 1.PRISMA diagram.
Studies of arthroplasty in sub-Saharan Africa.
| Author (date) | Country | GNIPC (US$) | Patients (n) (bilateral) | Age (years) (range) | Sex | Indication | HIV (% on HAART) | Mean CD4 cells/mm[ | Mean length of stay (days) (range) | Inpatient mortality (%) | Mean follow-up (months) (range) | Mean preoperative outcome measure (range) | Mean postop outcome measure (range) | Complications | Revisions (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||||
| Katchy et al.[ | Nigeria | 5750 | 52 (16) | 63.5 (55–77) | 32 F 20 M | 100% OA | No data | All over 14 days (no range) | 1.9 | No mean | OKS 12 (no range) | OKS 45.5 (no range) | 1.9% superficial infection 1.9% foot drop 1.9% varus malalignment 1.9% stroke | 1.9 | |
| Graham et al.[ | Malawi | 320 | 127 (26) | 65.3 (24–84) | 98 F 29 M | 99% OA <1% AVN <1% RA <1% Sickle cell | 6 | No data | 8.2 (5–20) | 0 | 51 (6–126) | OKS 16.81 (4–36) | OKS 45.61 (29–48) | 0.7% aseptic loosening 2.0% deep infection | 2.6 |
| Anyaehie et al.[ | Nigeria | 5750 | 38 (7) | 62.6 (41–85) | 7 M 31 F | 76% OA 20% PTOA 4% Post surgery | No data | Min 14 | 0 | 32 (13–52) | KSS 21.35 (0–51) | KSS 88 (60–100) | 8.9% common per nerve palsy 4.4% superficial infection 2.2% sacral sore 2.2% fracture 2.2% deep infection | No data | |
| Lisenda et al.[ | Botswana | 16710 | 170 (23) | 64.5 | 34 M 159 F | 98% OA 2% RA | No data | 7 | 2 | 0 | No data | No data | 0.7% pulmonary embolism | No data | |
| Lisenda et al.[ | Botswana | 16710 | 51 (7) | 65.6 (46–81) 3 | 5 M 53 F | 92% OA 8% RA | 0 All excluded | No data | 3 | No mean (26–47) | No data | No data | 1.7% deep infection 1.7% dislocation | 1.7 | |
| Kigera and Kimpiatu[ | Kenya | 1380 | 231 | 67.3 | M:F 1:3 | 96% OA | No data | No data | No data | 16 (0–149) | No data | No data | 3.9% superficial infection 2.6% deep infection | 2.6 | |
| George and Ofori-Atta[ | Ghana | 4160 | 7 (1) | 59.3 (38–71) | 6 F 1 M | 88% OA 12% PTOA | No data | 10 (5–12) | 0 | 6 (3–12) | OKS 15.5 (4–24) | OKS 44.5 (35–59) | 12.5% loosening | 12.5 | |
|
| |||||||||||||||
| Lisenda et al.[ | Botswana | 16710 | 143 (10) | 64.5 | 98 M 55 F | 64% OA 31% AVN 3% DDH 2% RA | No data | 7 | 0 | 0 | No data | No data | 0 | No data | |
| Lisenda et al.[ | Botswana | 16710 | 41 (1) | 66.2 (43–86) | 25 M 17 F | 76% OA 22% AVN 2% TB | 0 All excluded | No data | 0 | No mean (26–47) | No data | No data | 2.4% dislocation | 0 | |
| Dossche et al.[ | Burkina Faso | 1730 | 136 (16) | 49 (21–78) | 86 M 53 F | 40% AVN 37% OA 23% Fracture | No data | No data | 1 | Min 6–8 | No data | No data | 11.2% fracture 0.7% femoral nerve palsy 0.7% burn 1.3% haemolysis 0.7% PE 1.3% dislocation | 6.6 | |
| Graham et al.[ | Malawi | 320 | 29 (14) | 47 (21–59) | 19 M 10 F | 80% AVN 6.5%AVN 6.5% Post TB 4% NOF 2% Perthes | 100 (100) | 489 (183–1017) | No data | 0 | 42 (6–98) | HHS 27 (5–56) | HHS 86 (73–91) | 0 | 0 |
| Kingori and Gakuu[ | Kenya | 1380 | 97 (2) | No data | No data | No data | No data | No data | 0 | No data | No data | No data | 2.0% dislocation 2.0% superficial infection 2.0% fracture 2.0% DVT 1.0% deep infection 1.0% upper GI bleed 1.0% haematoma 1.0% sciatic nerve palsy | 1.0 | |
| Lubega et al.[ | Malawi | 320 | 58 (15) | 52 (18–73) | 33 M 25 F | 49% AVN 30% OA 10% Fracture 4% Malunion 3% Perthes 1% GCT 1% TB | 33 positive 58 tested | 543 (183–1410) | 10 (7–19) | 0 | No data | HHS 29 (9–59) | HHS 85 (79–91) | 2.7% dislocation 1.4% pulmonary embolism 1.4% aseptic loosening | 1.4 |
|
| |||||||||||||||
| Mulla et al.[ | Zambia | 3850 | TKR 7 THR 43 Rev THR 1 | 58.4 | 21 M | 71% OA | 33 positive | No data | No data | TKR 0 THR 0 | Min 1 | No data | No data | TKR 0 THR 7.0% dislocation 4.7% infection | No data |
TKR and TKR data combined.
Details of implants and cementing techniques used.
| Author (date) | Implant details | Cementing details |
|---|---|---|
|
| ||
| Katchy et al.[ | 68 DePuy Biomet PS | No data |
| Graham et al.[ | 171 DePuy CR PFC 2 DePuy CS PFC 4 Biomet AGC | All Smartset GHV |
| Anyaehie et al.[ | All Johnson and Johnson PFC Sigma | All Palacos |
| Lisenda et al.[ | No data | 145 cemented 42 hybrid 6 uncemented |
| Lisenda et al.[ | Smith and Nephew Profix | 26 cemented 26 hybrid 6 uncemented |
| Kigera and Kimpiatu[ | 81 DePuy 12 Zimmer | All cemented 2 g Gentamicin in 40 g cement |
| George and Ofori-Atta[ | No Data | No data |
|
| ||
| Lisenda et al.[ | No data | 147 uncemented 6 hybrid |
| Lisenda et al.[ | 41 Smith and Nephew porous synergy 1 Spectron Hip 15 Reflection Spiked Acetabulum 27 R3 Acetabulum | All uncemented |
| Dossche et al.[ | 141 Charnley or Kheos 3 Vives Femur | All femurs cemented 5 uncemented acetabulum 147 cemented acetabulum |
| Graham et al.[ | 45 Charnley and Ogee 3 Biomet Stanmore | All Smartset GHV |
| Kingori and Gakuu[ | No data | All cemented |
| Lubega et al.[ | 43 Charnley and Ogee 29 Biomet Stanmore | All Smartset GHV |
|
| ||
| Mulla et al.[ | No data | No data |
Head sizes and approaches used in THRs.
| Author (date) | Dislocation rate (%) | Mean follow-up (months) (range) | Head sizes (mm) | Head size (dislocated) (mm) | Approaches used (%) |
|---|---|---|---|---|---|
|
| |||||
| Lisenda et al.[ | 0 | 0 | No data | N/A | Anterolateral 100 |
| Lisenda et al.[ | 2.4 | No mean (26–47) | 36 (57.1%) 32 (4.8%) 28 (38.1%) | 28 (100%) | Anterolateral 100 |
| Dossche et al.[ | 1.3 | Min 6–8 | No data | No data | Anterolateral 100 |
| Graham et al.[ | 0 | 42 (6–98) | Insufficient data | N/A | No data |
| Kingori and Gakuu[ | 1 | No data | No data | No data | Anterolateral 95 Posterior 5 |
| Lubega et al.[ | 1.4 | No data | Insufficient data | No data | No data |
|
| |||||
| Mulla et al.[ | 7 | Min 1 | 28 (51.6%) Missing data in 48.4% | No data | Hardinge 84.3 |